{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T14:50:33Z","timestamp":1787496633058,"version":"build-2736575974"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","diabetesresearchclinicalpractice.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Research and Clinical Practice"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1016\/j.diabres.2021.108958","type":"journal-article","created":{"date-parts":[[2021,7,16]],"date-time":"2021-07-16T11:52:09Z","timestamp":1626436329000},"page":"108958","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["Simplification of complex insulin therapy: a story of dogma and therapeutic resignation"],"prefix":"10.1016","volume":"178","author":[{"given":"Dario","family":"Giugliano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Scappaticcio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Longo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Caruso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Ida","family":"Maiorino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Bellastella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Esposito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.diabres.2021.108958_b0005","series-title":"Zebra Cards: an aid to obscure diagnoses","author":"Sotos","year":"2006"},{"key":"10.1016\/j.diabres.2021.108958_b0010","doi-asserted-by":"crossref","unstructured":"Turner RC, Ward EA, Phillips MA, Dornan TL, Ward GM, Hockaday TDR. Continuous subcutaneous insulin infusion or subcutaneous insulin injections Lancet. 1979;314(8140):481","DOI":"10.1016\/S0140-6736(79)91543-5"},{"key":"10.1016\/j.diabres.2021.108958_b0015","doi-asserted-by":"crossref","unstructured":"American Diabetes Association. 11. Older adults: standards of medical care in diabetes\u20142021. Diabetes Care. 2021;44(Suppl. 1):S168\u2013179.","DOI":"10.2337\/dc21-S012"},{"issue":"18","key":"10.1016\/j.diabres.2021.108958_b0020","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1056\/NEJMoa0905479","article-title":"Three-year efficacy of complex insulin regimens in type 2 diabetes","volume":"361","author":"Holman","year":"2009","journal-title":"N Engl J Med."},{"issue":"8","key":"10.1016\/j.diabres.2021.108958_b0025","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.2337\/dc13-3010","article-title":"Factors associated with weight gain in people with type 2 diabetes starting on insulin","volume":"37","author":"Balkau","year":"2014","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.diabres.2021.108958_b0030","doi-asserted-by":"crossref","first-page":"104","DOI":"10.2337\/dc17-1669","article-title":"The association of severe hypoglycemia with incident cardiovascular events and mortality in adults with type 2 diabetes","volume":"41","author":"Lee","year":"2018","journal-title":"Diabetes Care"},{"issue":"9618","key":"10.1016\/j.diabres.2021.108958_b0035","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/S0140-6736(08)60485-7","article-title":"Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomised controlled trial","volume":"371","author":"Bretzel","year":"2008","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.diabres.2021.108958_b0040","doi-asserted-by":"crossref","first-page":"240","DOI":"10.2337\/dc09-1348","article-title":"Correlates of insulin injection omission","volume":"33","author":"Peyrot","year":"2010","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1016\/j.diabres.2021.108958_b0045","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1111\/j.1463-1326.2011.01512.x","article-title":"Proportion of patients at HbA1c target <7% with eight classes of antidiabetic drugs in type 2 diabetes: systematic review of 218 randomized controlled trials with 78,945 patients","volume":"14","author":"Esposito","year":"2012","journal-title":"Diabetes Obes Metab."},{"issue":"2","key":"10.1016\/j.diabres.2021.108958_b0050","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.2337\/dc17-1826","article-title":"Comment on Edelman and Polonsky. Type 2 diabetes in the real world: The elusive nature of glycemic control","volume":"41","author":"Giugliano","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2021.108958_b0055","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1111\/dom.12485","article-title":"Patient-level meta-analysis of the EDITION 1, 2 and 3 studies: glycaemic control and hypoglycaemia with new insulin glargine 300 U\/ml versus glargine 100 U\/ml in people with type 2 diabetes","volume":"17","author":"Ritzel","year":"2015","journal-title":"Diabetes Obes Metab."},{"issue":"3","key":"10.1016\/j.diabres.2021.108958_b0060","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1001\/jamainternmed.2014.7345","article-title":"Potential overtreatment of diabetes mellitus in older adults with tight glycemic control","volume":"175","author":"Lipska","year":"2015","journal-title":"JAMA Intern Med."},{"issue":"4","key":"10.1016\/j.diabres.2021.108958_b0065","doi-asserted-by":"crossref","first-page":"468","DOI":"10.2337\/dc16-0985","article-title":"Trends in drug utilization, glycemic control, and rates of severe hypoglycemia, 2006\u20132013","volume":"40","author":"Lipska","year":"2017","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.diabres.2021.108958_b0070","doi-asserted-by":"crossref","first-page":"69","DOI":"10.2337\/dc17-1414","article-title":"Long-term trends in antidiabetes drug usage in the U.S.: Real-world evidence in patients newly diagnosed with type 2 diabetes","volume":"41","author":"Montvida","year":"2018","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1016\/j.diabres.2021.108958_b0075","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1007\/s00125-020-05370-7","article-title":"Potential diabetes overtreatment and risk of adverse events among older adults in Ontario: a population-based study","volume":"64","author":"Lega","year":"2021","journal-title":"Diabetologia"},{"key":"10.1016\/j.diabres.2021.108958_b0080","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1001\/jama.2011.490","article-title":"Clinical inertia as a clinical safeguard","volume":"305","author":"Giugliano","year":"2001","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.diabres.2021.108958_b0085","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s40618-018-0951-8","article-title":"Clinical inertia, reverse clinical inertia, and medication non-adherence in type 2 diabetes","volume":"42","author":"Giugliano","year":"2019","journal-title":"J Endocrinol Invest."},{"issue":"8","key":"10.1016\/j.diabres.2021.108958_b0090","doi-asserted-by":"crossref","first-page":"569","DOI":"10.7326\/M17-0939","volume":"168","author":"Qaseem","year":"2018","journal-title":"Ann Intern Med."},{"key":"10.1016\/j.diabres.2021.108958_b0095","doi-asserted-by":"crossref","unstructured":"American Diabetes Association. 9. Pharmacologic approaches to glycemic treatment: Standards of Medical Care in Diabetes\u20142021. Diabetes Care. 2021;44(Suppl. 1): S111\u2013S124.","DOI":"10.2337\/dc21-S009"},{"issue":"4","key":"10.1016\/j.diabres.2021.108958_b0100","doi-asserted-by":"crossref","first-page":"614","DOI":"10.2337\/dc16-1957","article-title":"Insulin and glucagon-like peptide 1 receptor agonist combination therapy in type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials","volume":"40","author":"Maiorino","year":"2017","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2021.108958_b0105","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.diabres.2019.06.009","article-title":"The good companions: insulin and glucagon-like peptide-1 receptor agonist in type 2 diabetes. A systematic review and meta-analysis of randomized controlled trials","volume":"154","author":"Maiorino","year":"2019","journal-title":"Diabetes Res Clin Pract."},{"issue":"7","key":"10.1016\/j.diabres.2021.108958_b0110","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1111\/dom.13724","article-title":"Deintensification in older patients with type 2 diabetes: a systematic review of approaches, rates and outcomes","volume":"21","author":"Seidu","year":"2019","journal-title":"Diabetes Obes Metab."},{"issue":"7","key":"10.1016\/j.diabres.2021.108958_b0115","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1001\/jamainternmed.2016.2288","article-title":"Simplification of insulin regimen in older adults and risk of hypoglycemia","volume":"176","author":"Munshi","year":"2016","journal-title":"JAMA Intern Med."},{"issue":"7","key":"10.1016\/j.diabres.2021.108958_b0120","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/S2213-8587(15)00204-1","article-title":"SGLT inhibition and euglycaemic diabetic ketoacidosis","volume":"3","author":"Hine","year":"2015","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"1","key":"10.1016\/j.diabres.2021.108958_b0125","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1111\/dom.12785","article-title":"Sodium-glucose co-transporter 2inhibitors in addition to insulin therapy for management of type 2 diabetes mellitus: a meta-analysis of randomized controlled trials","volume":"19","author":"Tang","year":"2017","journal-title":"Diabetes Obes Metab."},{"issue":"1","key":"10.1016\/j.diabres.2021.108958_b0130","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1111\/jdi.12654","article-title":"Satisfaction of switching to combination therapy with lixisenatide and basal insulin in patients with type 2 diabetes receiving multiple daily insulin injection therapy: a randomized controlled trial","volume":"9","author":"Miya","year":"2018","journal-title":"J Diabetes Investig."},{"issue":"5","key":"10.1016\/j.diabres.2021.108958_b0135","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1007\/s13300-019-0673-8","article-title":"Simplifying Complex insulin regimens while preserving good glycemic control in type 2 diabetes","volume":"10","author":"Taybani","year":"2019","journal-title":"Diabetes Ther."},{"key":"10.1016\/j.diabres.2021.108958_b0140","doi-asserted-by":"crossref","DOI":"10.1111\/jdi.13533","article-title":"Simplification of complex insulin regimens using canagliflozin or liraglutide in patients with well-controlled type 2 diabetes: A 24-week randomized controlled trial","author":"Ando","year":"2021","journal-title":"J Diabetes Investig."},{"issue":"10","key":"10.1016\/j.diabres.2021.108958_b0145","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.2337\/dc19-2316","article-title":"Impact of a weekly glucagon-like peptide 1 receptor agonist, albiglutide, on glycemic control and on reducing prandial insulin use in type 2 diabetes inadequately controlled on multiple insulin therapy: A randomized trial","volume":"43","author":"Rosenstock","year":"2020","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1016\/j.diabres.2021.108958_b0150","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.2337\/dc20-2623","article-title":"Feasibility of simplification from a basal-bolus insulin regimen to a fixed-ratio formulation of basal insulin plus a GLP-1RA or to basal insulin plus an SGLT2 inhibitor: BEYOND, a randomized, pragmatic trial","volume":"44","author":"Giugliano","year":"2021","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2021.108958_b0155","doi-asserted-by":"crossref","unstructured":"Basu S, Yudkin JS, Kehlenbrik S, al. Estimation of global insulin use for type 2 diabetes, 2018-2030: a microsimulation analysis. Lancet Diabetes Endocrinol. 2019;7:25\u201333.","DOI":"10.1016\/S2213-8587(18)30303-6"},{"issue":"1","key":"10.1016\/j.diabres.2021.108958_b0160","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1111\/jgs.15616","article-title":"Tools for deprescribing in frail older persons and those with limited life expectancy: a systematic review","volume":"67","author":"Thompson","year":"2019","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.diabres.2021.108958_b0165","doi-asserted-by":"crossref","first-page":"107922","DOI":"10.1016\/j.diabres.2019.107922","article-title":"Beyond basal-bolus insulin regimen: Is it still the ultimate chance for therapy in diabetes?","volume":"157","author":"Giugliano","year":"2019","journal-title":"Diabetes Res Clin Pract"}],"container-title":["Diabetes Research and Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016882272100317X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016882272100317X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T19:18:22Z","timestamp":1759173502000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016882272100317X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":33,"alternative-id":["S016882272100317X"],"URL":"https:\/\/doi.org\/10.1016\/j.diabres.2021.108958","relation":{},"ISSN":["0168-8227"],"issn-type":[{"value":"0168-8227","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Simplification of complex insulin therapy: a story of dogma and therapeutic resignation","name":"articletitle","label":"Article Title"},{"value":"Diabetes Research and Clinical Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diabres.2021.108958","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"108958"}}